Pharsight

Humalog Kwikpen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5514646 LILLY Insulin analogs modified at position 29 of the B chain
May, 2013

(11 years ago)

US5474978 LILLY Insulin analog formulations
Jun, 2014

(9 years ago)

US7291132 LILLY Medication dispensing apparatus with triple screw threads for mechanical advantage
Aug, 2024

(2 months from now)

Humalog Kwikpen is owned by Lilly.

Humalog Kwikpen contains Insulin Lispro Recombinant.

Humalog Kwikpen has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Humalog Kwikpen are:

  • US5514646
  • US5474978

Humalog Kwikpen was authorised for market use on 15 November, 2019.

Humalog Kwikpen is available in injectable;injection dosage forms.

Humalog Kwikpen can be used as treatment of diabetes mellitus, use for the treatment of hyperglycemia.

The generics of Humalog Kwikpen are possible to be released after 09 August, 2024.

Drug Exclusivity Drug Exclusivity Expiration
NR(NR) Oct 12, 2015

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Use for the treatment of hyperglycemia; Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

More Information on Dosage

HUMALOG KWIKPEN family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6551992 ELI LILLY AND CO Stable insulin formulations
Jun, 2018

(5 years ago)

US6034054 ELI LILLY AND CO Stable insulin formulations
Jun, 2018

(5 years ago)

US7291132 ELI LILLY AND CO Medication dispensing apparatus with triple screw threads for mechanical advantage
Aug, 2024

(2 months from now)

Humalog Kwikpen is owned by Eli Lilly And Co.

Humalog Kwikpen contains Insulin Lispro Recombinant.

Humalog Kwikpen has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Humalog Kwikpen are:

  • US6551992
  • US6034054

Humalog Kwikpen was authorised for market use on 26 May, 2015.

Humalog Kwikpen is available in solution;subcutaneous dosage forms.

Humalog Kwikpen can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof..

The generics of Humalog Kwikpen are possible to be released after 09 August, 2024.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 26 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

HUMALOG KWIKPEN family patents

Family Patents